Serving the Society Since 1986
Advanced Search
Volume 22 Issue 6
December 2007
    Citation: Lei KANG, Jing HU, Xue-shan XIA, Jian-guo WU. HIV and HCV: from Co-infection to Epidemiology, Transmission, Pathogenesis, and Treatment .VIROLOGICA SINICA, 2007, 22(6) : 443-450.
    shu

    HIV and HCV: from Co-infection to Epidemiology, Transmission, Pathogenesis, and Treatment

    • 1.

      The State Key Laboratory of Virology, College of Life Sciences, Wuhan University, Wuhan 430072, China

    • 2.

      College of Life Sciences, Kunming University of Science and Technology, Kunming 650224, China

    • Corresponding author: Jian-guo WU, jwu@whu.edu.cn;wu9988@vip.sina.com
    • Received Date: 24 September 2007
      Accepted Date: 08 November 2007
      Available online: 01 December 2007
    • Human immunodeficiency virus (HIV) is the infectious agent causing acquired immu- nodeficiency syndrome (AIDS), a deadliest scourge of human society. Hepatitis C virus (HCV) is a major causative agent of chronic liver disease and infects an estimated 170 million people worldwide, resulting in a serious public health burden. Due to shared routes of transmission, co-infection with HIV and HCV has become common among individuals who had high risks of blood exposures. Among hemophiliacs the co-infection rate accounts for 85%; while among injection drug users (IDU) the rate can be as high as 90%. HIV can accelerate the progression of HCV-related liver disease, particularly when immunodeficiency has developed. Although the effect of HCV on HIV infection is controversial, most studies showed an increase in mortality due to liver disease. HCV may act as a direct cofactor to fasten the progression of AIDS and decrease the tolerance of highly active antiretroviral therapy (HARRT). Conversely, HAART-related hepatotoxicity may enhance the progression of liver fibrosis. Due to above complications, co-infection with HCV and HIV-1 has imposed a critical challenge in the management of these patients. In this review, we focus on the epidemiology and transmission of HIV and HCV, the impact of the two viruses on each other, and their treatment.
    • 加载中

      1. Alter M J. 2002. Prevention of spread of hepatitis C. Hepatology, 36: S93-98.
          doi: 10.1002/(ISSN)1527-3350

      2. Brandee L. 2003. Influence of maternal human imm- unodeficiency virus (HIV) co-infection on vertical transmission of hepatitis C virus (HCV): a meta-analysis. Int J Epidemiol, 32: 727-734.
          doi: 10.1093/ije/dyg107

      3. Brau N, Salvatore M, Rios-Bedoya C F, et al. 2006.Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antire- troviral therapy. J Hepatol, 44: 47-55.
          doi: 10.1016/j.jhep.2005.07.006

      4. Busch M P, Kleinman S H, Jackson B, et al. 2000.Nucleic acid amplification testing of blood donors for transfusion-transmitted infectious diseases: report of the Interorganizational Task Force on Nucleic Acid Amplifi- cation Testing of Blood Donors.Transfusion, 40: 143-159.
          doi: 10.1046/j.1537-2995.2000.40020143.x

      5. Busch M P. 2001. Closing the windows on viral transmission by blood transfusion. In: Blood safety in the new millennium (Stramer S L. ed.). AABB Press: Bethesda. p33-54.

      6. Cardo D M, Culver D H, Ciesielski C A, et al. 1997. A case-control study of HIV seroconversion in health care workers after percutaneous exposure. New Engl J Med, 337: 1485-1490.
          doi: 10.1056/NEJM199711203372101

      7. Crespo M, Sauleda S, Esteban J I, et al. 2007.Peginterferon alpha-2b plus ribavirin vs interferon alpha-2b plus ribavirin for chronic hepatitis C in HIV-coinfected patients. J Viral Hepatitis, 14: 228-238.
          doi: 10.1111/jvh.2007.14.issue-4

      8. Daar E S, Lynn H, Donfield S, et al. 2001. Hepatitis Cvirus load is associated with human immunodeficiency virus type 1 disease progression in hemophiliacs. J Infect Dis, 183: 589-595.
          doi: 10.1086/jid.2001.183.issue-4

      9. Darby S C, Ewart D W, Giangrande P L, et al. 1997.Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C. UK Haemophilia Centre Directors' Organisation. Lancet, 350: 1425-1431.
          doi: 10.1016/S0140-6736(97)05413-5

      10. Di Bisceglie A M. 2000. Natural history of hepatitis C: its impact on clinical management. Hepatology, 31: 1014- 1018.
          doi: 10.1053/he.2000.5762

      11. Dimitrakopoulos A, Takou A, Haida A, et al. 2000. The prevalence of hepatitis B and C in HIV-positive Greek patients: relationship to survival of deceased AIDS patients. J Infection, 40: 127-131.
          doi: 10.1053/jinf.1998.0636

      12. Fainboim H, Gonzalez J, Fassio E, et al. 1999.Prevalence of hepatitis viruses in an anti-human imm- unodeficiency virus-positive population from Argentina. A multicentre study. J Viral Hepatitis, 6: 53-57.
          doi: 10.1046/j.1365-2893.1999.00005.x

      13. Fialaire P, Payan C, Vitour D, et al. 1999. Sustained disappearance of hepatitis C viremia in patients receiving protease inhibitor treatment for human immunodeficiency virus infection. J Infect Dis, 180: 574-575.
          doi: 10.1086/jid.1999.180.issue-2

      14. Gavazzi G, Richallet G, Morand P, et al. 1998. Effects of double and triple antiretroviral agents on the HCV viral load in patients coinfected with HIV and HCV. Patho Biol, 46: 412-415.

      15. Giordano T P, Kramer J R, Souchek J, et al. 2004.Cirrhosis and hepatocellular carcinoma in HIV-infected veterans with and without the hepatitis C virus: a cohort study, 1992-2001. Arch Intern Med, 164: 2349-2354.
          doi: 10.1001/archinte.164.21.2349

      16. Greub G, Ledergerber B, Battegay M, et al. 2000.Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet, 356: 1800-1805.
          doi: 10.1016/S0140-6736(00)03232-3

      17. Hoffmann C, Rockstroh J, Kamps B S. 2005. HIV and HBV/HCV Coinfections, Paris, Cagliari, Wuppertal, Sevilla: Flying Publisher, 487.

      18. Landesman S H, Kalish L A, Burns D N, et al. 1996.Obstetrical factors and the transmission of human immunodeficiency virus type 1 from mother to child. The Women and Infants Transmission Study. New Engl J Med, 334: 1617-1623.
          doi: 10.1056/NEJM199606203342501

      19. Lauer G M, Nguyen T N, Day C L, et al. 2002. Human immunodeficiency virus type 1-hepatitis C virus coinfection: intraindividual comparison of cellular immune responses against two persistent viruses. J Virol, 76: 2817- 2826.
          doi: 10.1128/JVI.76.6.2817-2826.2002

      20. Lesens O, Deschenes M, Steben M, et al. 1999. Hepatitis C virus is related to progressive liver disease in human immunodeficiency virus-positive hemophiliacs and should be treated as an opportunistic infection. J Infect Dis, 179: 1254-1258.
          doi: 10.1086/jid.1999.179.issue-5

      21. Macias J, Castellano V, Merchante N, et al. 2004. Effect of antiretroviral drugs on liver fibrosis in HIV-infected patients with chronic hepatitis C: harmful impact of nevirapine. AIDS, 18: 767-774.
          doi: 10.1097/00002030-200403260-00007

      22. Marcellin P, Boyer N, Gervais A, et al. 1997. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferonalpha therapy. Ann Intern Med, 127: 875-881.
          doi: 10.7326/0003-4819-127-10-199711150-00003

      23. Matthews-Greer J M, Caldito G C, Adley S D, et al.2001. Comparison of hepatitis C viral loads in patients with or without human immunodeficiency virus. Clin Diagn Lab Immun, 8: 690-694.

      24. Mauss S, Rockstroh J K. 2005. HCV/HIV-coinfection－is there a state of the art after APRICOT and RIBAVIC? J Antimicrob Chemoth, 56: 615-618.
          doi: 10.1093/jac/dki277

      25. McHutchison J G, Gordon S C, Schiff E R, et al. 1998.Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med, 339: 1485- 1492.
          doi: 10.1056/NEJM199811193392101

      26. Mohsen A H, Easterbrook P J, Taylor C, et al. 2003.Impact of human immunodeficiency virus (HIV) infection on the progression of liver fibrosis in hepatitis C virus infected patients. Gut, 52: 1035-1040.
          doi: 10.1136/gut.52.7.1035

      27. National Institutes of Health Consensus Development Conference Statement. 2002. Management of hepatitis C. Hepatology, 36 (5 Suppl 1): S3-20.

      28. Neau D, Trimoulet P, Winnock M, et al. 2001. Impact of protease inhibitors on intrahepatic hepatitis C virus viral load.AIDS, 15: 1736-1738.
          doi: 10.1097/00002030-200109070-00021

      29. Poynard T., Marcellin P., Lee S S, et al. 1998.Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet, 352: 1426-1432.
          doi: 10.1016/S0140-6736(98)07124-4

      30. Ragni M V, Bontempo F A. 1999. Increase in hepatitis C virus load in hemophiliacs during treatment with highly active antiretroviral therapy. J Infect Dis, 180: 2027-2029.
          doi: 10.1086/jid.1999.180.issue-6

      31. Rancinan C, Neau D, Saves M, et al. 2002. Is hepatitis C virus co-infection associated with survival in HIV-infected patients treated by combination antiretroviral therapy? AIDS, 16: 1357-1362.
          doi: 10.1097/00002030-200207050-00007

      32. Rutschmann O T., Negro F., Hirschel B, et al. 1998.Impact of treatment with human immunodeficiency virus (HIV) protease inhibitors on hepatitis C viremia in patients coinfected with HIV. J Infect Dis, 177: 783-785.
          doi: 10.1086/jid.1998.177.issue-3

      33. Sherman K E, Rouster S D, Chung R T, et al. 2002. Hepatitis C virus prevalence among patients coinfected with human immunodeficiency virus: a cross-sectional analysis of the U.S. adult AIDS clinical trials group. Clin Infect Dis, 34: 831-837.
          doi: 10.1086/339042

      34. Sherman M, Yoshida E M, Deschenes M, et al. 2006. Peginterferon alfa-2a (40KD) plus ribavirin in chronic hepatitiss C patients who failed previous interferon therapy. Gut, 55:1631-1638.
          doi: 10.1136/gut.2005.083113

      35. Shiratori Y, Imazeki F, Moriyama M, et al. 2000.Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med, 132: 517-524.

      36. Soriano V, Bravo R, García-Samaniego J, et al. 1997.Relapses of chronic hepatitis C in HIV-infected patients who responded to interferon therapy. Hepatitis/HIV Spanish Study Group. [Letter]. AIDS, 11: 400-401.

      37. Soto B, Rodrigo L, Garcia-Bengoechea M, et al. 1994. Heterosexual transmission of hepatitis C virus and the possible role of coexistent human immunodeficiency virus infection in the index case. A multicentre study of 423 pairings. J Intern Med, 236: 515-519.
          doi: 10.1111/joim.1994.236.issue-5

      38. Staples C T Jr, Rimland D, Dudas D. 1999. Hepatitis C in the HIV (human immuno- deficiency virus) Atlanta V. A. (Veterans Affairs Medical Center) Cohort Study (HAVACS): the effect of coinfection on survival. Clin Infect Dis, 29: 150-154.
          doi: 10.1086/524645

      39. Strasfeld L, Yungtai L O, Netski D, et al. 2003. The association of hepatitis C prevalence, activity, and genotype with HIV infection in a cohort of New York City drug users. JAIDS, 33: 356-364.

      40. Sulkowski M S, Moore R D, Mehta S H, et al. 2002.Hepatitis C and progression of HIV disease.JAMA, 288: 199-206.
          doi: 10.1001/jama.288.2.199

      41. Tedaldi E M, Baker R K, Moorman A C, et al. 2003. Influence of coinfection with hepatitis C virus on morbidity and mortality due to human immunodeficiency virus infection in the era of highly active antiretroviral therapy. Clin Infect Dis, 36: 363-367.
          doi: 10.1086/cid.2003.36.issue-3

      42. Tedaldi E M, Hullsiek K H, Malvestutto C D, et al. 2003.Prevalence and characteristics of hepatitis C virus coinfection in a human immunodeficiency virus clinical trials group: the Terry Beirn Community Programs for Clinical Research on AIDS. Clin Infect Dis, 36:1313-1317.
          doi: 10.1086/cid.2003.36.issue-10

      43. Tedeschi R, Pivetta E, Zanussi S, et al. 2003.Quantification of hepatitis C virus (HCV) in liver specimens and sera from patients with human imm- unodeficiency virus coinfection by using the versant HCV RNA 3.0 (Branched DNA-Based) DNA assay. J Clin Microbiol, 41: 3046-3050.
          doi: 10.1128/JCM.41.7.3046-3050.2003

      44. Thomas D L, Vlahov D, Solomon L, et al. 1995.Correlates of hepatitis C virus infections among injection drug users. Medicine, 74:212-220.
          doi: 10.1097/00005792-199507000-00005

      45. Thomas D L, Astemborski J, Rai R M, et al. 2000. The natural history of hepatitis C virus infection: host, viral, and environmental factors.JAMA, 284: 450-456.

      46. Torre D, Tambini R, Cadario F, et al. 2001. Evolution of coinfection with human immuno- deficiency virus and hepatitis C virus in patients treated with highly active antiretroviral therapy. Clin Infect Dis, 33: 1579-1585.
          doi: 10.1086/cid.2001.33.issue-9

      47. Torriani F J, Soriano V. 2000. Chronic hepatitis C in HIVinfected individuals. AIDS Reviews, 2:168-177.

      48. Trimoulet P, Neau D, Le Bail B, et al. 2002. Intrahepatic HCV RNA loads in 37 HIV-HCV co-infected patients with controlled HIV infection. J Med Virol, 67: 143-151.
          doi: 10.1002/jmv.v67:2

      49. Velati C, Romano L, Baruffi L, et al. 2002. Residual risk of transfusion-transmitted HCV and HIV infections by antibody-screened blood in Italy. Transfusion, 42:989-993.
          doi: 10.1046/j.1537-2995.2002.00173.x

      50. Verma S, Wang C H, Govindarajan S, et al. 2006. Do type and duration of antiretroviral therapy attenuate liver fibrosis in HIV-hepatitis C viruscoinfected patients? Clin Infect Dis, 42: 262-270.
          doi: 10.1086/499055

      51. Wright T L, Hollander H, Pu X, et al. 1994. Hepatitis C in HIV infected patients with and without AIDS: prevalence and relationship to patient survival. Hepatology, 20: 1152-1155.
          doi: 10.1002/(ISSN)1527-3350

      52. Yee T T, Griffioen A, Sabin C A, et al. 2000. The natural history of HCV in a cohort of hemophilic patients infected between 1961 and 1985. Gut, 47: 845-851.
          doi: 10.1136/gut.47.6.845

      53. Yokozaki S, Takamatsu J, Nakano I, et al. 2000.Immunologic dynamics in hemophiliac patients infected with hepatitis C virus and human immunodeficiency virus: influence of antiretroviral therapy. Blood, 96: 4293-4299.

      54. Zhang C, Yang R, Xia X, et al. 2002. High prevalence of HIV-1 and hepatitis C virus coinfection among injection drug users in the southeastern region of Yunnan, China. JAIDS, 29: 191-196.

      55. Zylberberg H, Benhamou Y, Lagneaux J L, et al. 2000.Safety and efficacy of interferon-ribavirin combination therapy in HCV-HIV coinfected subjects: an early report.Gut, 47: 694-697.
          doi: 10.1136/gut.47.5.694

    • 加载中
    PDF

    Article Metrics

    Article views(4272) PDF downloads(18) Cited by()

    Related
    Proportional views

      HIV and HCV: from Co-infection to Epidemiology, Transmission, Pathogenesis, and Treatment

        Corresponding author: Jian-guo WU, jwu@whu.edu.cn;wu9988@vip.sina.com
      • 1. The State Key Laboratory of Virology, College of Life Sciences, Wuhan University, Wuhan 430072, China
      • 2. College of Life Sciences, Kunming University of Science and Technology, Kunming 650224, China
      • Received Date: 24 September 2007
      • Accepted Date: 08 November 2007

      Abstract: Human immunodeficiency virus (HIV) is the infectious agent causing acquired immu- nodeficiency syndrome (AIDS), a deadliest scourge of human society. Hepatitis C virus (HCV) is a major causative agent of chronic liver disease and infects an estimated 170 million people worldwide, resulting in a serious public health burden. Due to shared routes of transmission, co-infection with HIV and HCV has become common among individuals who had high risks of blood exposures. Among hemophiliacs the co-infection rate accounts for 85%; while among injection drug users (IDU) the rate can be as high as 90%. HIV can accelerate the progression of HCV-related liver disease, particularly when immunodeficiency has developed. Although the effect of HCV on HIV infection is controversial, most studies showed an increase in mortality due to liver disease. HCV may act as a direct cofactor to fasten the progression of AIDS and decrease the tolerance of highly active antiretroviral therapy (HARRT). Conversely, HAART-related hepatotoxicity may enhance the progression of liver fibrosis. Due to above complications, co-infection with HCV and HIV-1 has imposed a critical challenge in the management of these patients. In this review, we focus on the epidemiology and transmission of HIV and HCV, the impact of the two viruses on each other, and their treatment.

        HTML

      EPIDEMIOLOGY AND TRANSMISSION